<DOC>
	<DOCNO>NCT02733367</DOCNO>
	<brief_summary>This Phase 3 , open-label , single-group , non-randomised , observational study safety biochemical disease control Infacort速 neonate , infant child AI complete study Infacort 003 . All subject satisfactorily complete study Infacort 003 offer opportunity take part Infacort 004 .</brief_summary>
	<brief_title>Extension Study Patients Entered Into Study Infacort 003</brief_title>
	<detailed_description>This Phase 3 , open-label , single-group , non-randomised , observational study safety biochemical disease control Infacort速 neonate , infant child AI complete study Infacort 003 ( EudraCT number 2014-002265-30 ) . All subject satisfactorily complete study Infacort 003 offer opportunity participate study Infacort 004 final visit study Infacort 003 . Subjects receive usual clinically-appropriate dose ( since bioequivalence demonstrate conventional hydrocortisone ) , determine Investigator , administer accord usual clinical practice - generally 3 4 time day . Subjects continue treat study meet study withdrawal criterion , Infacort速 grant marketing authorisation ( available commercially , expect within 2 year initiation study ) , Infacort速 refuse marketing authorisation , Sponsor decide discontinue study .</detailed_description>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<criteria>Subjects successfully complete study Infacort 003 , whose inclusion criterion : 1 . Male female child le 6 year age . 2 . A diagnosis adrenal insufficiency ( AI ) confirm inappropriately low cortisol usually support test . 3 . Receiving appropriate adrenocortical replacement therapy ( hydrocortisone with/without fludrocortisone ) . 4 . Adequately hydrate nourished . In addition , parents/carers must able understand give write Informed Consent extension study . 1 . Clinically evident acute AI ( adrenal crisis ) ( Note : subject reevaluate eligibility episode ) 2 . Inability child take oral therapy 3 . Subjects clinical sign acute infection fever inclusion ( Note : subject reevaluate eligibility episode ) 4 . Any surgical medical condition opinion Investigator may place subject high risk his/her participation study 5 . Parents/carers subject unwilling consent save propagation pseudonymised medical data study reason 6 . Subjects dependent relationship Investigator Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>